http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102345943-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2012-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102345943-B1 |
| titleOfInvention | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| abstract | The present invention relates to a method for assessing (analyzing) the risk of a potential adverse effect on a human patient mediated by administering a CD19xCD3 bispecific antibody to the human patient, comprising the method comprising the B cell to T cell ratio of said patient wherein a ratio of about 1:5 or less is indicative of a risk of a potential adverse effect on the patient, or determines the total number of B cells in the patient, wherein less than about 50 B cells per μl of peripheral blood including total B cell count indicative of risk of potential adverse effects on the patient. Accordingly, the present invention provides a method (dose regimen) for administering a CD19xCD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or less and/or a total B cell number of less than about 50 B cells per μl of peripheral blood. A method comprising the steps of: (a) administering a first dose of said antibody for a first period of time; and continuously (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose. In some embodiments, a third dose of said antibody is administered for a third period. Such dosing regimens may be applied to methods of treating malignant CD19 positive lymphocytes or ameliorating and/or preventing adverse effects mediated by administration of said bispecific antibody. The invention also relates to the use of a CD19xCD3 bispecific antibody for the manufacture of a pharmaceutical composition to be used in the method of the invention. Also disclosed is a pharmaceutical package or kit comprising said antibody in a first dose and a second dose and optionally a third dose as defined in the method/administration regimen of the present invention. |
| priorityDate | 2011-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 360.